Asthma News

News

Tezepelumab improves lung function in severe asthma

20211019060000

In the treatment of patients with severe, uncontrolled asthma, use of tezepelumab appears to produce rapid and sustained improvements in lung function, as reported in a study.

Allergic status does not blunt benefits of LAMA/LABA in Asians with asthma

One in 10 Singaporeans affected by asthma

Tristan Manalac, 20211015090000

A recent multi-ethnic Singapore study confirms that asthma is a common disease, affecting more than 10 percent of adults, especially former smokers and those with high body mass index (BMI). Asthma is also associated with worse health-related quality of life (HRQoL), making it a substantial public health concern.

SGLT2 inhibitors help ward off asthma

20211012060000

Patients on sodium-glucose co-transporter (SGLT) 2 inhibitors are less likely to develop asthma compared with those on dipeptidyl peptidase (DPP)-4 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), a study has found.

As-needed budesonide–formoterol as good as ICS maintenance in mild asthma

Inhaled JAK inhibitor cuts exhaled nitric oxide in mild asthma

20210929060000

GDC-0214, an inhaled Janus kinase (JAK) inhibitor, induces dose-dependent reductions in fractional exhaled nitric oxide in patients with mild asthma, a recent study has found.

Educational intervention improves lung function, quality of life, inflammatory profile in asthmatics

20210926060000

An educational intervention for proper inhaled corticosteroid use helps improve lung function, quality of life, and control of inflammation among asthma patients, a recent study has found.

Mepolizumab benefits held up over time

Elvira Manzano, 20210925000000

Beyond 1 year, the humanized monoclonal antibody mepolizumab maintained real-world efficacy and safety in patients with severe eosinophilic asthma in the REALITI-A cohort study, reports an expert at ERS 2021.

The air we breathe in the workplace: Is it safe?

Audrey Abella, 20210924100000

What used to be a place that holds a perception of relative safety and minimal health risk to its occupants, the office now appears to be a place that is inching its way towards the other side of the respiratory health spectrum, with office-related occupational asthma on the rise, according to findings from a UK cross-sectional study presented at ERS 2021.

Kids with asthma who are obese likely to respond poorly to ICS

Kids with asthma who are obese respond poorly to ICS

Pearl Toh, 20210922141000

Children with asthma are less likely to respond to inhaled corticosteroid (ICS) if they also happen to obese or overweight, suggests a study presented at ERS 2021.

Mepolizumab benefits patients with severe asthma across the board

Omalizumab stops proliferation, transformation of fibrocytes in severe allergic asthma

20210902110000

The anti-immunoglobulin (Ig) E therapy omalizumab lessens the number of circulating fibrocytes, cell and number of fibrocytes, and α-smooth muscle actin (α-SMA)+ fibrocytes after 3–7 days of culture in patients with severe allergic asthma (SAA), a study has shown.

Azithromycin confers no effect on bronchial wall thickness, increases lumen area, radius

20210821060000

In patients with severe persistent asthma, treatment with azithromycin helps increase the bronchial lumen radius and lumen area, as shown in a study. However, it appears to have no significant effect on wall thickness.

New asthma guide: What doctors should know

Pearl Toh, 26 Nov 2020

Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.

Kids hard-hit by Delta; which ART performs best?

Elvira Manzano, 24 Oct 2021

That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.